PREDICTING MEASURABLE RESIDUAL DISEASE FOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS POSTTRANSPLANTATION

被引：0

作者：

Wang, Yue-Wen ^{[1
,2
]}

Fu, Guo-Mei ^{[1
,2
]}

Xu, Lan-Ping ^{[1
,2
]}

Wang, Yu ^{[1
,2
]}

Cheng, Yi-Fei ^{[1
,2
]}

Zhang, Yuan-Yuan ^{[1
,2
]}

Zhang, Xiao-Hui ^{[1
,2
]}

Liu, Yan-Rong ^{[1
,2
]}

Liu, Kai-Yan ^{[1
,2
]}

Huang, Xiao-Jun ^{[1
,2
]}

Chang, Ying-Jun ^{[1
,2
]}

机构：

[1] Peking Univ Peoples Hosp, Beijing, Peoples R China

[2] Peking Univ Inst Hematol, Beijing, Peoples R China

来源：

BONE MARROW TRANSPLANTATION | 2024年 / 59卷

关键词：

D O I：

暂无

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

P516

引用

页码：498 / 498

页数：1

共 50 条

[31] Measurable Residual Disease Analysis by Flow Cytometry and Correlation With Molecular Measurable Residual Disease in Acute Promyelocytic Leukemia [J].

Wen, Zhihao ;

Xue, Xinran ;

Li, Shuhua ;

Liu, Yu ;

Jin, Yongmei ;

Jiang, Nenggang ;

Liao, Hongyan .

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2025, 149 (03) :262-270

[32] Current assessment and management of measurable residual disease in patients with acute lymphoblastic leukemia in the setting of CAR-T-cell therapy [J].

Lin Minghao ;

Zhao Xiaosu ;

Chang Yingjun ;

Zhao Xiangyu .

中华医学杂志英文版, 2024, 137 (02)

[33] Monitoring Measurable Residual/Relapsing Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia [J].

Wethmar, K. ;

Matern, S. ;

Esseling, E. ;

Bruggemann, M. ;

Schliemann, C. ;

Berdel, W. E. ;

Lenz, G. ;

Stelljes, M. .

ANNALS OF HEMATOLOGY, 2019, 98 :S57-S57

[34] Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia [J].

Bazinet, Alexandre ;

Kadia, Tapan M. ;

Short, Nicholas ;

Borthakur, Gautam ;

Wang, Sa A. ;

Loghavi, Sanam ;

Jorgensen, Jeffrey L. ;

Patel, Keyur P. ;

DiNardo, Courtney D. ;

Daver, Naval ;

Alvarado, Yesid ;

Haddad, Fadi ;

Pierce, Sherry A. ;

Nogueras Gonzalez, Graciela M. ;

Maiti, Abhishek ;

Andreeff, Michael ;

Jabbour, Elias ;

Konopleva, Marina ;

Huang, Xuelin ;

Kantarjian, Hagop ;

Ravandi, Farhad .

BLOOD, 2022, 140 :2267-2269

[35] METHODS FOR THE MINIMUM RESIDUAL DISEASE MONITORING IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA [J].

Parovichnikova, E. N. ;

Mavrina, E. S. ;

Surin, V. L. ;

Savchenko, V. G. .

GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2013, 58 (03) :45-48

[36] Updates on lymphoblastic leukemia/lymphoma classification and minimal/ measurable residual disease analysis [J].

Kovach, Alexandra E. ;

Wood, Brent L. .

SEMINARS IN DIAGNOSTIC PATHOLOGY, 2023, 40 (06) :457-471

[37] Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia [J].

Roug, Anne Stidsholt ;

Ommen, Hans Beier .

CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (04)

[38] Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia [J].

Anne Stidsholt Roug ;

Hans Beier Ommen .

Current Treatment Options in Oncology, 2019, 20

[39] Perspective on measurable residual disease testing in acute myeloid leukemia [J].

Walter, Roland B. .

LEUKEMIA, 2024, 38 (01) :10-13

[40] Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia [J].

Azenkot, Tali ;

Jonas, Brian A. .

CANCERS, 2022, 14 (15)

← 1 2 3 4 5 →